TCGA-44-6145-01A-11R-1755-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 62
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.550
- ALLOGRAFT_REJECTION+0.490
- INTERFERON_ALPHA_RESPONSE+0.490
- COMPLEMENT+0.460
- PROTEIN_SECRETION+0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.420
- IL6_JAK_STAT3_SIGNALING+0.400
- TGF_BETA_SIGNALING+0.350
- UV_RESPONSE_DN+0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
Top 10 suppressed
- MYC_TARGETS_V2-0.590
- MYC_TARGETS_V1-0.280
- OXIDATIVE_PHOSPHORYLATION-0.270
- E2F_TARGETS-0.250
- SPERMATOGENESIS-0.240
- KRAS_SIGNALING_DN-0.220
- WNT_BETA_CATENIN_SIGNALING-0.160
- G2M_CHECKPOINT-0.150
- NOTCH_SIGNALING-0.140
- UNFOLDED_PROTEIN_RESPONSE-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-5941-01A-11R-1755-07 | — | cohortA1 | 0.891 |
| 2 | TCGA-A8-A0A1-01A-11R-A00Z-07 | — | A | 0.864 |
| 3 | TCGA-78-7160-01A-11R-2039-07 | — | cohortA4 | 0.856 |
| 4 | SJEPD031078_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.850 |
| 5 | TCGA-A8-A096-01A-11R-A00Z-07 | — | B | 0.848 |
| 6 | SRR934924 | — | — | 0.843 |
| 7 | TCGA-44-A4SS-01A-11R-A24X-07 | — | cohortA1 | 0.839 |
| 8 | TCGA-44-6779-01A-11R-1858-07 | — | cohortA1 | 0.835 |
| 9 | ERR2208957 | — | — | 0.834 |
| 10 | TCGA-A2-A0EV-01A-11R-A034-07 | — | B | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.550 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| COMPLEMENT | 0.460 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.440 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.420 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.350 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.340 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.290 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.260 | Inavolisib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |